Sichenzia Ross Friedman Ference LLP Advises Amarantus on $5M PIPE Investment from Discover Growth Fund
New York, NY – April 29, 2015 – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced today that the Firm has represented Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company focused on developing diagnostics in neurology, and therapeutic products in the areas of neurology, psychiatry, ophthalmology and orphan diseases, on a $5 million investment from Discover Growth Fund.
Pursuant to the transaction’s Stock Purchase Agreement, Amarantus issued 1,087 shares of designated Series G Preferred stock at a fixed price of $0.06 per share for gross proceeds of $5,000,000. The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey J. Fessler and Marcelle Balcombe.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)
- Sichenzia Ross Ference LLP Represents Document Security Systems, Inc. in $5.6 Million Underwritten Public Offering of Common Stock - June 11, 2019
- New Jersey Bureau of Securities Proposes New Rule to Create State-Level Fiduciary Duties For Broker-Dealers, Associated Persons, Investment Advisers and Investment Adviser Representatives - June 11, 2019
- Sichenzia Ross Ference LLP Represents Medicine Man Technologies, Inc. in Private Placement Offering of up to $14 Million - June 11, 2019